Single-tablet HIV Treatment Shows Better Outcomes Over Multi-tablet Regimen | Latest News RSS feed

Single-tablet HIV Treatment Shows Better Outcomes Over Multi-tablet Regimen - Latest News


Single-tablet HIV treatment shows better outcomes over multi-tablet regimen

Taking one tablet per day, versus multiple tablets, appears to result in better outcomes for HIV patients. Credit: Mitch Mirkin HIV patients on a single-tablet daily regimen had better treatment reten... read more

Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients

Findings from the study demonstrated that the single tablet regimen (STR) D/C/F/TAF provided ... and safety of D/C/F/TAF versus the control in HIV-1 positive treatment-naïve adult patients over 48 wee... read more

Medicaid policy may deny access to HIV medication

The U.S. Department of Health and Human Services raised concerns about the safety of Atripla over ... single-tablet regimens are where HIV treatment is headed, and having these regimens instead of pat... read more

Looking for another news?


Gilead Sciences' (GILD) Management Presents at Piper Jaffray Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Jaffray Healthcare Conference December 3, 2014 9:30 AM ET Executives Paul Carter - EVP, Commercial Operations Pat O'Brien - VP, IR Analysts Joshua Schimmer - ... read more


Pharm Exec's 2015 Brand of the Year: Sovaldi and Harvoni for Hepatitis C

And while Gilead remains tightly focused on the anti-viral business, HCV has—at least for the moment—eclipsed the company’s traditional weight in the HIV ... single tablet, administered orally for a s... read more

HIV Treatment Adds Safe Once-a-Day Pill

But the findings are still beneficial, as evidence shows people who receive treatment for HIV do better with single-tablet, once-daily dosing ... Ultimately, the regimen can improve a patient's outcom... read more

Gilead Sciences' CEO Presents at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) The 30th Annual JPMorgan Chase Healthcare Conference ... the treatment of HIV. We partnered with Bristol-Myers and Merck with their efavirenz to combine it with Tru... read more

Studies continue to support tenofovir alafenamide combination pill as it nears US approval

Other research showed that the new formulation works better ... of TAF vs TDF single-tablet regimen in HIV-1 treatment-naive black and nonblack patients through week 48. IDWeek, abstract 1073, 2015. D... read more

Gilead Sciences Management Discusses Q3 2012 Results - Earnings Call Transcript

Total utilization of single tablet regimens for naive patients was boosted by Eviplera to a new high of nearly 30%. Eviplera is now the #2 regimen in HIV naive patients ... depending on the outcome. I... read more

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

Acknowledgment: The authors thank Kelly Gebo, MD, MPH, and the HIV Research Network for supplying helpful data. Grant Support: By grants R37-AI42006 and R01-AI093269 from the National Institute of All... read more

Better outcomes for patients using single-pill combination for blood pressure

People who are prescribed a combination pill to manage their high blood pressure are more likely to take their medicine as instructed and have better health outcomes than ... saving one in 40 lives ov... read more

Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

The integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV ... better resistance profile than earlier drugs in the class, could be administered once dail... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us